Novel IEF Peptide Fractionation Method Reveals a Detailed Profile of N-Terminal Acetylation in Chemotherapy-Responsive and -Resistant Ovarian Cancer Cells

Abstract

The new agreement specifically addresses what authors can do with different versions of their manuscript -e.g. use in theses and collections, teaching and training, conference presentations, sharing with colleagues, and posting on websites and repositories. The terms under which these uses can occur are clearly identified to prevent misunderstandings that could jeopardize final publication of a manuscript (Section II, Permitted Uses by Authors). Easy Reference User Guide Posting Accepted and Published Works on Websites and Repositories:A digital file of the Accepted Work and/or the Published Work may be made publicly available on websites or repositories (e.g. the Author's personal website, preprint servers, university networks or primary employer's institutional websites, third party institutional or subject-based repositories, and conference websites that feature presentations by the Author(s) based on the Accepted and/or the Published Work) under the following conditions:• It is mandated by the Author(s)' funding agency, primary employer, or, in the case of Author(s) employed in academia, university administration.• If the mandated public availability of the Accepted Manuscript is sooner than 12 months after online publication of the Published Work, a waiver from the relevant institutional policy should be sought. If a waiver cannot be obtained, the Author(s) may sponsor the immediate availability of the final Published Work through participation in the ACS AuthorChoice program-for information about this program see http://pubs.acs.org/page/policy/authorchoice/index.html.• If the mandated public availability of the Accepted Manuscript is not sooner than 12 months after online publication of the Published Work, the Accepted Manuscript may be posted to the mandated website or repository. The following notice should be included at the time of posting, or the posting amended as appropriate: "This document is the Accepted Manuscript version of a Published Work that appeared in final form in [JournalTitle], copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see [insert ACS Articles on Request authordirected link to Published Work, see http://pubs.acs.org/page/policy/articlesonrequest/index.html]." • The posting must be for non-commercial purposes and not violate the ACS' "Ethical Guidelines to Publication of Chemical Research" (see http://pubs.acs.org/ethics).• Regardless of any mandated public availability date of a digital file of the final Published Work, Author(s) may make this file available only via the ACS AuthorChoice Program. For more information, see http://pubs.acs.org/page/policy/authorchoice/index.html. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59

Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations

“…Both cell lines were cultured with the addition of 10% foetal bovine serum (Bovogen Biologicals, East Keilor, VIC, Australia) supplemented with 1% penicillin/streptomycin (Sigma Aldrich, St. Louis, MO, USA) and 1% L-glutamine (Sigma Aldrich, St. Louis, MO, USA). OVCAR-5 and CaOV3 cells were made resistant to CBP after treatment with 6–8 cycles of CBP (50 μM, Hospira Australia, Pty Ltd., Mulgrave, VIC, Australia) [ 27 , 28 ]. Resistance to CBP was measured regularly, and CBPR cell lines were seen to be at least two-fold more resistant to CBP than their parental partners through the following experiments.…”

Digging for Missing Proteins Using Low-Molecular-Weight Protein Enrichment and a “Mirror Protease” Strategy

“…Until now, 2186 MPs (PE2–4) were still undetected, even after the use of special enrichments , and the most sensitive protein detection approaches (2018-01) . We drew the molecular weight (MW) distribution for the MPs and found that the MPs were mainly distributed in the LMW districts, especially in the 10–40 kDa range (Figure A).…”

Ovarian Blood Sampling Identifies Junction Plakoglobin as a Novel Biomarker of Early Ovarian Cancer

“…5438040100, Sigma-Aldrich)). LC-MS/MS was carried out using an Impact HD mass spectrometer (Bruker Daltonics, Bremen, Germany) as described earlier ( 18 ), deviating in applying a flow-rate of 0.3 μl/min and a 70 min gradient for peptide separation. Ten μl of peptide mixture was injected.…”